Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RaySearch Laboratories AB ( ($SE:RAY.B) ) has provided an update.
RaySearch Laboratories has created a new Corporate Development & Strategy department and appointed Jenna Styan, previously a senior executive at Siemens Healthineers (Varian), to lead it as Director from 1 April 2026 and join the group management team. With her extensive experience in global oncology software, treatment planning system sales and clinical solutions across EMEA, along with a clinical background in radiotherapy, Styan’s hire is intended to sharpen RaySearch’s strategic capabilities, support future growth and reinforce its competitive positioning in the oncology software and cancer therapy technology market.
The most recent analyst rating on ($SE:RAY.B) stock is a Buy with a SEK255.00 price target. To see the full list of analyst forecasts on RaySearch Laboratories AB stock, see the SE:RAY.B Stock Forecast page.
More about RaySearch Laboratories AB
RaySearch Laboratories AB is a Stockholm-based medical technology company specializing in innovative software for improved cancer treatment. Its portfolio includes the RayStation treatment planning system and the RayCare oncology information system, as well as newer products such as the RayIntelligence oncology analytics platform and the RayCommand treatment control system. RaySearch’s software is used by more than 1,100 clinics in 47 countries, and the company, a spin-off from the Karolinska Institute founded in 2000, has been listed on Nasdaq Stockholm since 2003.
Average Trading Volume: 143,525
Technical Sentiment Signal: Buy
Current Market Cap: SEK7.78B
For an in-depth examination of RAY.B stock, go to TipRanks’ Overview page.